Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles

Caspase-cleaved proteins are released from disintegrated apoptotic cells and can be detected in the circulation. We here addressed whether caspase-cleaved cytokeratin 18 (CK18-Asp396) can be used as a serum biomarker for assessment of the clinical efficiency of chemotherapy in hormone-refractory pro...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2006-06, Vol.94 (11), p.1592-1598
Main Authors: Kramer, G, Schwarz, S, Hägg, M, Havelka, A Mandic, Linder, S
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antineoplastic Agents, Phytogenic - administration & dosage
Antineoplastic Agents, Phytogenic - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Apoptosis - drug effects
Biological and medical sciences
Biomarkers - blood
Biomedical and Life Sciences
Biomedicine
Cancer Research
Caspases - blood
Clinical Study
Docetaxel
Drug Administration Schedule
Drug Resistance
Epidemiology
Humans
Keratins - blood
Male
Medical sciences
Medicin och hälsovetenskap
Middle Aged
Molecular Medicine
Nephrology. Urinary tract diseases
Oncology
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
Taxoids - administration & dosage
Taxoids - therapeutic use
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Vinblastine - analogs & derivatives
Vinblastine - therapeutic use
Vinorelbine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Caspase-cleaved proteins are released from disintegrated apoptotic cells and can be detected in the circulation. We here addressed whether caspase-cleaved cytokeratin 18 (CK18-Asp396) can be used as a serum biomarker for assessment of the clinical efficiency of chemotherapy in hormone-refractory prostate cancer (HRPC). A total of 82 patients with HRPC were evaluated during 751 treatment cycles, either with estramustine (EMP)/vinorelbine or with EMP/docetaxel. The levels of CK18-Asp396 and of total CK18 were measured in patient serum before and during therapy by ELISA. Docetaxel induced significant increases in serum CK18-Asp396 ( P
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6603129